Targeting SUMOylation in glioblastoma: A novel avenue for therapy and biomarker discovery

TL;DR

This paper explores how SUMOylation, a protein modification, contributes to glioblastoma and suggests targeting it as a new therapy and biomarker approach.

Contribution

The paper identifies Ubc9 and SAE1 as novel therapeutic targets in glioblastoma through their roles in SUMOylation.

Findings

SUMOylation influences glioblastoma malignancy via cell cycle regulation and PKB/AKT signaling.

Ubc9 promotes tumor proliferation and aggressiveness, making it a promising therapeutic target.

SAE1 correlates with glioblastoma grade and affects cell cycle regulators like CDK6.

Abstract

SUMOylation, a post-translational protein modification, plays a crucial role in regulating various biological processes. Dysregulation of SUMOylation has been linked to glioblastoma progression, impacting key signaling pathways. This review summarizes the current knowledge on SUMOylation's role in glioma malignancy, highlighting its influence on cell cycle regulation, PKB/AKT signaling pathway, and microRNA expression. Our work identifies Ubc9 as a promising therapeutic target due to its role in enhancing SUMOylation, promoting glioblastoma aggressiveness, and facilitating tumor proliferation. Additionally, SAE1 correlates with glioblastoma grade and affects cell cycle regulators, while SUMOylation stabilizes CDK6, driving the G1/S transition. Targeting these pathways with inhibitors, such as topotecan and chlorogenic acid, may provide novel treatment strategies. Furthermore, SUMOylation-driven alterations in transcription factors and DNA repair mechanisms contribute to therapy resistance. Understanding these mechanisms could pave the way for innovative interventions in glioblastoma management.

Figures